J
Jane Huang
Researcher at Genentech
Publications - 56
Citations - 4489
Jane Huang is an academic researcher from Genentech. The author has contributed to research in topics: Bruton's tyrosine kinase & Ibrutinib. The author has an hindex of 16, co-authored 54 publications receiving 3368 citations.
Papers
More filters
Journal ArticleDOI
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman,Michael D. Prados,Patrick Y. Wen,Tom Mikkelsen,David Schiff,Lauren E. Abrey,W. K. Alfred Yung,Nina Paleologos,Martin K. Nicholas,Randy L. Jensen,James J. Vredenburgh,Jane Huang,Maoxia Zheng,Timothy F. Cloughesy +13 more
TL;DR: Bvacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
Journal ArticleDOI
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Bonnie K. Harrington,Susan O'Brien,Jeffrey A. Jones,Anna Schuh,S Devereux,Jorge M. Chaves,William G. Wierda,Farrukh T. Awan,Jennifer R. Brown,Peter Hillmen,Deborah M. Stephens,Paolo Ghia,Jacqueline C. Barrientos,John M. Pagel,Jennifer A. Woyach,Dave Johnson,Jane Huang,Xiaolin Wang,Allard Kaptein,Brian J. Lannutti,Todd Covey,Maria Fardis,Jesse McGreivy,Ahmed Hamdy,Wayne Rothbaum,Raquel Izumi,Thomas G. Diacovo,Amy J. Johnson,Richard R. Furman +29 more
TL;DR: In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.
Journal ArticleDOI
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Constantine S. Tam,Stephen Opat,Shirley D'Sa,Wojciech Jurczak,Hui Peng Lee,Gavin Cull,Gavin Cull,Roger G. Owen,Paula Marlton,Paula Marlton,Björn E. Wahlin,Ramón García Sanz,Helen McCarthy,Stephen P. Mulligan,Alessandra Tedeschi,Jorge J. Castillo,Jarosław Czyż,Carlos Fernández de Larrea,David Belada,Edward N. Libby,Jeffrey Matous,Marina Motta,Tanya Siddiqi,Monica Tani,Marek Trneny,Monique C. Minnema,Christian Buske,Veronique Leblond,Judith Trotman,Judith Trotman,Wai Y. Chan,Jingjing Schneider,Sunhee Ro,Aileen Cohen,Jane Huang,Meletios A. Dimopoulos +35 more
TL;DR: Zanubrutinib treatment was associated with a trend toward better response quality and less toxicity, particularly cardiovascular toxicity, which demonstrate that zanubRutinIB and ibrut inib are highly effective in the treatment of WM.
Journal ArticleDOI
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam,Judith Trotman,Judith Trotman,Stephen Opat,Jan A. Burger,Gavin Cull,Gavin Cull,David Gottlieb,David Gottlieb,Rosemary Harrup,Rosemary Harrup,Patrick B. Johnston,Paula Marlton,Paula Marlton,Javier Munoz,John F. Seymour,D. Simpson,Alessandra Tedeschi,Rebecca Elstrom,Yiling Yu,Zhiyu Tang,Lynn Han,Jane Huang,William Novotny,Lai Wang,Andrew W. Roberts +25 more
TL;DR: Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities, and definition of the maximum tolerated dose (part 1).
Journal ArticleDOI
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Yuqin Song,Keshu Zhou,Dehui Zou,Jianfeng Zhou,Jianda Hu,Haiyan Yang,Huilai Zhang,Jie Ji,Wei Xu,Jie Jin,Fangfang Lv,Ru Feng,Sujun Gao,Haiyi Guo,Lei Zhou,Rebecca Elstrom,Jane Huang,William Novotny,Rachel Wei,Jun Zhu +19 more
TL;DR: These results demonstrate high and durable ORR and CR rates in patients with relapsed/refractory MCL and Zanubrutinib was generally well tolerated; grade ≥3 BTK inhibitor-associated toxicities were uncommon.